US stock futures flounder amid tech weakness, Fed caution
William Lewis (JO:LEWJ), Chair and CEO of Insmed Inc. (NASDAQ:INSM), has sold shares worth approximately $502,577, according to a recent SEC filing. The transactions, executed on April 1, 2025, involved multiple sales of common stock at prices ranging from $72.29 to $75.26 per share. The sales occurred near the stock’s current trading price of $73.33, with the company’s shares showing remarkable strength, having surged over 165% in the past year. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
In addition to these sales, Lewis exercised stock options to acquire 6,830 shares at a price of $10.85 per share, totaling $74,105. The acquired shares are held by the Katie Procter Dynasty Trust, reflecting indirect ownership. With analyst price targets ranging from $67.26 to $110, InvestingPro subscribers can access 10+ additional exclusive insights about Insmed’s valuation and growth prospects through the comprehensive Pro Research Report.
Following these transactions, Lewis’s holdings, including those held by the William Lewis Family Legacy Trust, remain significant, with a total of 334,186 shares directly owned and 50,500 shares indirectly owned. These transactions were conducted under a 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell stocks in accordance with insider trading laws. The company, currently valued at $13.28 billion, maintains a FAIR financial health score according to InvestingPro metrics.
In other recent news, Insmed Incorporated has been the subject of several analyst reports highlighting its potential in the pharmaceutical sector. RBC Capital Markets reaffirmed their Outperform rating with a $100 price target, focusing on the anticipated data for Insmed’s TPIP, which could significantly impact Pulmonary Vascular Resistance and the 6-Minute Walk Distance, two critical measures for the drug’s success. Similarly, Truist Securities maintained a Buy rating with a $108 price target, expressing confidence in the upcoming TPIP data for pulmonary arterial hypertension (PAH) and the commercial potential of brensocatib, pending its approval in 2025.
UBS also maintained a positive outlook, raising their price target to $110 while keeping a Buy rating, in anticipation of the Phase 2 data for TPIP. The UBS analysis emphasizes the importance of achieving a significant reduction in pulmonary vascular resistance, which could position TPIP as a preferred treatment option. H.C. Wainwright sustained a Buy rating with a $90 price target, highlighting Insmed’s innovative gene therapy approach for Duchenne muscular dystrophy, which demonstrated promising results in preclinical trials.
RBC Capital initiated coverage with an Outperform rating and a $100 price target, noting the potential success of brensocatib in the bronchiectasis market. The firm anticipates a peak sales opportunity of $8.2 billion, citing substantial demand and the lack of effective treatments. These recent developments underscore the confidence analysts have in Insmed’s pipeline and its potential to deliver value to investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.